Esketamine
Conditions
Keywords
closed-loop TCI, Esketamine, general anesthesia, NI
Brief summary
The propofol-refentanil program-controlled closed-loop target-controlled infusion system based on NI guidance has been clinically verified. In the case of clinical use of esketamine, the separation anesthesia properties do not affect the accuracy and safety of closed-loop system guidance. However, whether the specific degree of impact can be quantified, and based on quantitative indicators, this model can be better applied to a wider range of clinical actual conditions and different drug administration backgrounds.
Detailed description
The first phase is data collection on the effect of subanesthetic doses of esketamine on NI EEG in closed-loop target-controlled infusion systems for general anesthesia. According to the observation of pre-experiments and the latest literature at home and abroad, foreign studies have confirmed that esketamine does not affect the overall stability of the closed-loop system, and we verified the reliability of this conclusion through pre-experiments. In order to clarify the degree of influence of subanesthetic dose of esketamine on EEG, it is necessary to include a certain amount of esketamine applied to the anesthesia sample of closed-loop target controlled infusion system, through the main observation indicators: the change of EEG NI value after the administration of subanesthetic dose of esketamine during the anesthesia maintenance period, the change of EEG power spectrum, and the quantitative ratio change trend of brain waves (α, β, θ, δ waves). The difference in EEG NI value, power spectrum and dynamic transformation of brain wave increased due to the action of subanesthetic dose of esketamine was obtained, and the difference was quantified by the attribution of data to the degree of change of the actual EEG NI value. According to the preset guidance EEG NI value of the original closed-loop target-controlled infusion drug delivery system 36, the guidance preset value of the closed-loop system of 36+N in the clinical administration scenario of subanesthetic dose of esketamine was reset as the new EEG closed-loop feedback baseline. The second phase is the validation of the effect of esketamine equivalent to the subanesthetic dose on closed-loop target-controlled infusion general anesthesia based on regulated NI(36+N) feedback.
Interventions
DRUGSubanesthetic dose of esketamine
Both groups were given NI-guided propofol-refentanil dual-channel closed-loop target-controlled infusion under general anesthesia with a laryngeal mask/endotracheal intubation. The experimental group (EEG feedback index 36+N) and the control group (EEG feedback index 36) were intravenously injected esketamine 0.2mg∙kg-1 before anesthesia induction, followed by continuous 5μg∙kg-1∙min-1 infusion to maintain anesthesia for 30 minutes, and the maximum cumulative dose allowed was 100mg. In both groups, the infusion was stopped 30 minutes before the end of surgery.
Sponsors
bo xu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Participants were assigned to the management and control groups, and neither group of researchers nor subjects was clear about their group. Data statistical analysts and clinical trial participants maintain independence in their work.
Intervention model description
The control group chose the original preset value of 36 as the baseline value of EEG closed-loop feedback guidance (derived from the team's previous research results.The experimental group selected the preset value of 36+N as the baseline value of the new EEG closed-loop feedback guidance (the N value was 6-8 from the pre-experiment).Samples that met the inclusion criteria were randomized and randomly included in the experimental and control groups.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Patients undergoing laparoscopic general anesthesia surgery with anesthesia duration \> 60min, 2.18\ 55 years old, 3.BMI≥18.5kg/m2, 4. ASA Class I\ II
Exclusion criteria
* Exclude patients with any of the following criteria: 1. Contraindications to esketamine, propofol or refentanil; 2. Allergic reactions to egg/soy products; Hypersensitivity to fentanyl analogues; 3. Known/suspected neurological diseases, tumors, strokes, neurodegenerative diseases, severe head injuries, seizures, previous EEG abnormalities, cognitive deficits, acquired scalp/skull abnormalities, psychiatric diseases, severe depression, post-traumatic stress disorder, psychosis; 4. Taking psychotropic drugs within the past 7 days, 5. History of substance abuse/abuse or pregnancy in the past 30 days; 6. Currently involved in any other research involving drugs or devices.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| EEG value | From the beginning to the end of the surgery, an average of 4 hours | Differences in EEG values between the two groups based on different feedback baselines |
| Anesthesia maintains drug consumption | From the beginning to the end of the surgery, an average of 4 hours | Two groups of propofol and refentanil consumption |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| heart rate | From the beginning to the end of the surgery, an average of 4 hours | Rate variations and differences throughout the process |
| Blood pressure | From the beginning to the end of the surgery, an average of 4 hours | Changes and differences in blood pressure throughout the process |
| pulse | From the beginning to the end of the surgery, an average of 4 hours | Changes and differences in pulse throughout the process |
Contacts
Primary ContactBo Xu, professor
Outcome results
None listed